Accelerated Approvals Face More Pressure To Finish Trials; Midodrine A Concern

Midodrine hydrochloride, which seemingly takes the gold for most outstanding post-marketing studies among Subpart H approvals, soon may be pulled from the market, FDA warns application holders in an Aug. 18 letter